New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For BSX;STJ;MDT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 >>
February 5, 2016
08:05 EDTMDTMedtronic receives FDA approval for MRI CRT-D
Medtronic announced that it has received FDA approval for the first and only magnetic resonance imaging, or MRI, conditional cardiac resynchronization therapy defibrillators, or CRT-Ds, for the treatment of heart failure. The Medtronic Amplia MRI Quad CRT-D SureScan and Compia MRI Quad CRT-D SureScan systems are approved for MRI scans on any part of the body without positioning restrictions. Now, patients in the U.S. who receive these devices, which help treat their heart failure and reduce their risk of sudden cardiac arrest, have access to MRI scans if and when they need them. Both CRT-D systems will be commercially available in the coming months.
07:34 EDTBSXBoston Scientific 2016 results poised to beat expectations, says RBC Capital
Subscribe for More Information
06:36 EDTBSXBoston Scientific post-earnings selloff overdone, says Leerink
Subscribe for More Information
February 4, 2016
14:53 EDTBSXBoston Scientific weakness a buying opportunity, says BofA/Merrill
11:21 EDTBSXOptions with increasing call volume; FMC HST XME RIO BHP PAY DNDK BSX ALLY SWFT
10:20 EDTBSXHigh option volume stocks: EPC DK DNKN TTWO AVT VHC RL ZBH BSX AGCO
Subscribe for More Information
06:42 EDTBSXBoston Scientific reports Q4 adjusted EPS 26c, consensus 25c
Reports Q4 revenue $1.98B, consensus $1.99B.
February 3, 2016
14:48 EDTBSXNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include Philip Morris (PM), consensus 81c... AstraZeneca (AZN), consensus 88c... Occidental Petroleum (OXY), consensus (12c)... ConocoPhillips (COP), consensus (65c)... Cigna (CI), consensus $1.80... Intercontinental Exchange (ICE), consensus $3.01... Boston Scientific (BSX), consensus 25c... Charter Communications (CHTR), consensus (12c)... Ralph Lauren (RL), consensus $2.13... Dunkin' Brands (DNKN), consensus 50c... GrubHub (GRUB), consensus 14c... Level 3 (LVLT), consensus 53c... AmerisourceBergen (ABC), consensus $1.25... Cummins (CMI), consensus $2.11.
February 1, 2016
10:02 EDTMDTMedtronic announced CE Mark, commercial launch for Resolute Onyx expansion
Medtronic announced the recent CE Mark and commercial launch for an expanded size matrix of the Resolute Onyx DES, a next generation drug-eluting stent that is now available in 4.5mm and 5.0mm diameter sizes. The CE Mark also approved several new product indications including treatment of left main vessels and small vessels. Many coronary vessels are large in diameter of which a sub-set are left main, and now physicians can treat these large vessels with optimally sized stents that provide appropriate drug concentration. Resolute Onyx is the first DES available in these sizes among major manufacturers, offering the broadest size matrix to optimize the treatment of complex clinical scenarios. The Resolute Onyx DES is not commercially available in the United States.
08:05 EDTMDTMedtronic acquires Bellco
Medtronic announced it acquired privately-held Bellco, a pioneer in hemodialysis treatment solutions. Bellco's portfolio bolsters Medtronic's legacy renal access business and will be a foundational component of the company's recently formed Renal Care Solutions business. The Bellco transaction is expected to meet Medtronic's long-term financial metrics for acquisitions. Medtronic expects the net impact from the transaction to be earnings neutral in FY16 and neutral to accretive to earnings thereafter.
January 29, 2016
16:25 EDTMDTMedtronic to present transcatheter pacing data to FDA
Subscribe for More Information
January 28, 2016
11:11 EDTSTJHeartWare rallies after scrapping Valtech acquisition
The shares of HeartWare (HTWR) are surging after the company announced that would terminate its acquisition of privately held Valtech. Two research firms reacted positively to the news, with Leerink Swann saying that the company made the right decision, given its current difficulties and Raymond James upgrading HeartWare following the news. HeartWare develops and manufactures miniaturized implantable heart pumps, while Valtech has developed a method of replacing mitral valves in human hearts without the need for open heart surgery. WHAT'S NEW: HeartWare decided to terminate its acquisition of Valtech, the companies announced this morning. Pursuant to the terms of the agreement, HeartWare will make a $30M loan to Valtech in the form of a convertible promissory note. ANALYST REACTION: HeartWare's decision to abandon its acquisition of Valtech was correct in light of the problems that the company is facing with its next generation MVAD pump, Leerink analyst Danielle Antalffy wrote in a note to investors today. Noting that two weeks ago HeartWare announced that it would investigate suction issues that the device has had, the analyst says that fixing the pump could require additional investment, while it's uncertain how long it will take to solve the device's problems. However, the analyst remained upbeat on Heartware's current LVAD products, and believes that it can compete with next generation systems. She kept a $60 price target and Outperform rating on the shares. Raymond James upgraded HeartWare to Outperform from Market Perform, saying that the termination of the Valtech deal removes an overhang on the shares, while the stock's underperformance since September has made its valuation more attractive. Moreover, the stock does not appear to be giving any value to the problematic MVAD pump and the company has a 37% share of a $760M market that has only two main competitors and high barriers to entry, the firm wrote. WHAT'S NOTABLE: In early October 2015, activist investor Engaged Capital urged HeartWare to terminate the Valtech deal. Today HeartWare announced that it would, in conjunction with Engaged Capital, "jointly select" an independent party who will join Heartware's board. ANOTHER TO WATCH: HeartWare's chief rival, Thoratec, was acquired last year by St. Jude Medical (STJ). PRICE ACTION: In late morning trading, HeartWare rose 10% to $37.95. St. Jude, which reported its fourth quarter results and gave fiscal year guidance this morning, is down 1.4% to $53.56.
07:14 EDTBSXBoston Scientific and Accenture develop digital health solution
Subscribe for More Information
January 27, 2016
08:50 EDTSTJSt. Jude Medical sees FY16 CardioMEMS sales about $65M
Subscribe for More Information
07:19 EDTSTJSt. Jude Medical sees FY16 sales growth 2%-4%, consensus $6.12B
Subscribe for More Information
07:19 EDTSTJSt. Jude Medical sees Q1 adjusted EPS 87c-98c, consensus 94c
07:18 EDTSTJSt. Jude Medical reports Q4 CRM sales $580M, down 15% y/y
Subscribe for More Information
07:16 EDTSTJSt. Jude Medical reports Q4 adjusted EPS $1.02, consensus $1.01
Reports Q4 revenue $1.47B, consensus $1.47B.
January 26, 2016
14:32 EDTSTJNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include Novartis (NVS), consensus $1.18... Boeing (BA), consensus $1.26... United Technologies (UTX), consensus $1.52... Biogen (BIIB), consensus $4.08... EMC (EMC), consensus 65c... General Dynamics (GD), consensus $2.38... Anthem (ANTM), consensus $1.22... Illinois Tool Works (ITW), consensus $1.21... State Street (STT), consensus $1.18... Norfolk Southern (NSC), consensus $1.24... Progressive (PGR), consensus 47c... St. Jude Medical (STJ), consensus $1.01... Rockwell Automation (ROK), consensus $1.33... Textron (TXT), consensus 83c... Hess (HES), consensus ($1.47)... Cliffs Natural (CLF), consensus (26c).
07:04 EDTSTJSt. Jude Medical volatility flat into Q4 and outlook
Subscribe for More Information
<< 1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use